Last reviewed · How we verify
Anti-IL17
Anti-IL17 is a Anti-inflammatory Small molecule drug developed by Prof. Dr. Stephan Weidinger. It is currently in Phase 2 development for Psoriasis, Plaque psoriasis.
IL-17 inhibitor
Anti-IL17 has been studied in clinical trials for various skin conditions, including Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Psoriasis, Atopic Dermatitis, and CTCL/ Mycosis Fungoides. The treatment has been investigated in combination with Ixekizumab, a monoclonal antibody targeting IL17, and has also been compared to a placebo in clinical trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Anti-IL17 |
|---|---|
| Sponsor | Prof. Dr. Stephan Weidinger |
| Drug class | Anti-inflammatory |
| Target | IL-17 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Anti-IL17 drugs target the interleukin-17 cytokine, which plays a key role in inflammatory responses.
Approved indications
- Psoriasis
- Plaque psoriasis
Common side effects
- Injection site reaction
- Headache
- Nausea
Key clinical trials
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
- IL-17 Blockade to Decrease irAEs (REPLAY) (PHASE1)
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (PHASE2)
- Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) (PHASE2)
- Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (PHASE4)
- Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy (NA)
- Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women (NA)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-IL17 CI brief — competitive landscape report
- Anti-IL17 updates RSS · CI watch RSS
- Prof. Dr. Stephan Weidinger portfolio CI
Frequently asked questions about Anti-IL17
What is Anti-IL17?
How does Anti-IL17 work?
What is Anti-IL17 used for?
Who makes Anti-IL17?
What drug class is Anti-IL17 in?
What development phase is Anti-IL17 in?
What are the side effects of Anti-IL17?
What does Anti-IL17 target?
Related
- Drug class: All Anti-inflammatory drugs
- Target: All drugs targeting IL-17
- Manufacturer: Prof. Dr. Stephan Weidinger — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Psoriasis
- Indication: Drugs for Plaque psoriasis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing